Theiler's virus infection: Pathophysiology of demyelination and neurodegeneration

Pathophysiology

Volumn 18, Issue 1, 2011, Pages 31-41

  Sato, Fumitaka ^a   Tanaka, Hiroki ^a   Hasanovic, Faris ^b   Tsunoda, Ikuo ^a  

^a Louisiana State University School of Medicine Shreveport   (United States)

^b ARUP LABORATORIES   (United States)

Author keywords

Apoptosis; Autoimmunity; CD4 Positive T Lymphocytes; CD8 Positive T Lymphocytes; Microglia; Mouse Wld protein; Picornaviridae infections; Wallerian degeneration

Indexed keywords

GLIAL FIBRILLARY ACIDIC PROTEIN;

ALLERGIC ENCEPHALOMYELITIS; ARTICLE; AUTOIMMUNITY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CYTOTOXIC T LYMPHOCYTE; DEMYELINATION; HUMAN; IMMUNE RESPONSE; MACROPHAGE; MICROGLIA; MULTIPLE SCLEROSIS; MURINE ENCEPHALOMYELITIS VIRUS; NERVE CELL NECROSIS; NERVE DEGENERATION; NERVE FIBER DEGENERATION; NERVOUS SYSTEM INFLAMMATION; NEUROPATHOLOGY; OLIGODENDROGLIA; PRIORITY JOURNAL; VIRUS INFECTION; VIRUS PATHOGENESIS;

EID: 78650553553     PISSN: 09284680     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pathophys.2010.04.011     Document Type: Article

References (119)

1. Correale J., Fiol M. BHT-3009, a myelin basic protein-encoding plasmid for the treatment of multiple sclerosis. Curr. Opin. Mol. Ther. 2009, 11:463-470.
2. Kira J. Neuromyelitis optica and asian phenotype of multiple sclerosis. Ann. N. Y. Acad. Sci. 2008, 1142:58-71.
3. Johnson A.J., Suidan G.L., McDole J., Pirko I. The CD8 T cell in multiple sclerosis: suppressor cell or mediator of neuropathology?. Int. Rev. Neurobiol. 2007, 79:73-97.
4. Schwendimann R.N., Alekseeva N. Gender issues in multiple sclerosis. Int. Rev. Neurobiol. 2007, 79:377-392.
5. Luque F.A., Jaffe S.L. Cerebrospinal fluid analysis in multiple sclerosis. Int. Rev. Neurobiol. 2007, 79:341-356.
6. Jaffe S.L., Minagar A. Demyelinating pseudotumor. Arch. Neurol. 2005, 62:1466-1467.
7. Minagar A., Alexander J.S. Blood-brain barrier disruption in multiple sclerosis. Mult. Scler. 2003, 9:540-549.
8. García-Merino A., Barcenilla H., Díaz D., Monserrat J., Prieto A., Álvarez-Mon M. IFNβ therapy progressively normalizes the increased ex vivo T lymphocyte apoptosis observed in active patients with multiple sclerosis. Clin. Immunol. 2009, 132:195-202.
9. Berger J.R. Paradoxically aggressive multiple sclerosis in the face of natalizumab therapy. Mult. Scler. 2008, 14:708-710.
10. Tsunoda I., Fujinami R.S. Two models for multiple sclerosis: experimental allergic encephalomyelitis and Theiler's murine encephalomyelitis virus. J. Neuropathol. Exp. Neurol. 1996, 55:673-686.
11. Tsunoda I., Kuang L.-Q., Tolley N.D., Whitton J.L., Fujinami R.S. Enhancement of experimental allergic encephalomyelitis (EAE) by DNA immunization with myelin proteolipid protein (PLP) plasmid DNA. J. Neuropathol. Exp. Neurol. 1998, 57:758-767.
12. Takács K., Chandler P., Altmann D.M. Relapsing and remitting experimental allergic encephalomyelitis: a focused response to the encephalitogenic peptide rather than epitope spread. Eur. J. Immunol. 1997, 27:2927-2934.
13. Lehmann P.V., Forsthuber T., Miller A., Sercarz E.E. Spreading of T-cell autoimmunity to cryptic determinants of an autoantigen. Nature 1992, 358:155-157.
14. McRae B.L., Vanderlugt C.L., Dal Canto M.C., Miller S.D. Functional evidence for epitope spreading in the relapsing pathology of experimental autoimmune encephalomyelitis. J. Exp. Med. 1995, 182:75-85.
15. Bettelli E., Carrier Y., Gao W., Korn T., Strom T.B., Oukka M., Weiner H.L., Kuchroo V.K. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006, 441:235-238.
16. Korn T., Bettelli E., Gao W., Awasthi A., Jäger A., Strom T.B., Oukka M., Kuchroo V.K. IL-21 initiates an alternative pathway to induce proinflammatory T(H)17 cells. Nature 2007, 448:484-487.
17. Klemann C., Raveney B.J., Klemann A.K., Ozawa T., von Hörsten S., Shudo K., Oki S., Yamamura T. Synthetic retinoid AM80 inhibits Th17 cells and ameliorates experimental autoimmune encephalomyelitis. Am. J. Pathol. 2009, 174:2234-2245.
18. Pender M.P. An introduction to neuroimmunology. Autoimmune Neurological Disease 1995, 14-25. Cambridge University Press, Melbourne, (Chapter 2). M.P. Pender, P.A. McCombe (Eds.).
19. Huseby E.S., Liggitt D., Brabb T., Schnabel B., Öhlén C., Goverman J. A pathogenic role for myelin-specific CD8(+) T cells in a model for multiple sclerosis. J. Exp. Med. 2001, 194:669-676.
20. Sun D., Whitaker J.N., Huang Z., Liu D., Coleclough C., Wekerle H., Raine C.S. Myelin antigen-specific CD8+ T cells are encephalitogenic and produce severe disease in C57BL/6 mice. J. Immunol. 2001, 166:7579-7587.
21. Suzumura A., Silberberg D.H. MHC antigen expression on glial cells. Ann. N. Y. Acad. Sci. 1988, 540:495-497.
22. s mouse strains. Brain Pathol. 2000, 10:402-418.
23. Linington C., Bradl M., Lassmann H., Brunner C., Vass K. Augmentation of demyelination in rat acute allergic encephalomyelitis by circulating mouse monoclonal antibodies directed against a myelin/oligodendrocyte glycoprotein. Am. J. Pathol. 1988, 130:443-454.
24. Genain C.P., Cannella B., Hauser S.L., Raine C.S. Identification of autoantibodies associated with myelin damage in multiple sclerosis. Nat. Med. 1999, 5:170-175.
25. Ferguson B., Matyszak M.K., Esiri M.M., Perry V.H. Axonal damage in acute multiple sclerosis lesions. Brain 1997, 120:393-399.
26. Matthews P.M., De Stefano N., Narayanan S., Francis G.S., Wolinsky J.S., Antel J.P., Arnold D.L. Putting magnetic resonance spectroscopy studies in context: axonal damage and disability in multiple sclerosis. Semin. Neurol. 1998, 18:327-336.
27. Trapp B.D., Peterson J., Ransohoff R.M., Rudick R., Mörk S., Bö L. Axonal transection in the lesions of multiple sclerosis. N. Engl. J. Med. 1998, 338:278-285.
28. Tsunoda I., Fujinami R.S. Inside-Out versus Outside-In models for virus induced demyelination: axonal damage triggering demyelination, Springer. Semin. Immunopathol. 2002, 24:105-125.
29. Geurts J.J.G., Stys P.K., Minagar A., Amor S., Zivadinov R. Gray matter pathology in (chronic) MS: modern views on an early observation. J. Neurol. Sci. 2009, 282:12-20.
30. Bjartmar C., Kinkel R.P., Kidd G., Rudick R.A., Trapp B.D. Axonal loss in normal-appearing white matter in a patient with acute MS. Neurology 2001, 57:1248-1252.
31. Lovas G., Szilágyi N., Majtényi K., Palkovits M., Komoly S. Axonal changes in chronic demyelinated cervical spinal cord plaques. Brain 2000, 123:308-317.
32. Sharma R., Narayana P.A., Wolinsky J.S. Grey matter abnormalities in multiple sclerosis: proton magnetic resonance spectroscopic imaging. Mult. Scler. 2001, 7:221-226.
33. Pirko I., Lucchinetti C.F., Sriram S., Bakshi R. Gray matter involvement in multiple sclerosis. Neurology 2007, 68:634-642.
34. Gonzalez-Toledo E., Kelley R.E., Minagar A. Role of magnetic resonance spectroscopy in diagnosis and management of multiple sclerosis. Neurol. Res. 2006, 28:280-283.
35. Newcombe J., Gahan S., Cuzner M.L. Serum antibodies against central nervous system proteins in human demyelinating disease. Clin. Exp. Immunol. 1985, 59:383-390.
36. Terryberry J.W., Thor G., Peter J.B. Autoantibodies in neurodegenerative diseases: antigen-specific frequencies and intrathecal analysis. Neurobiol. Aging 1998, 19:205-216.
37. Bartoš A., Fialová L., Soukupová J., Kukal J., Malbohan I., Pit'ha J. Elevated intrathecal antibodies against the medium neurofilament subunit in multiple sclerosis. J. Neurol. 2007, 254:20-25.
38. Rawes J.A., Calabrese V.P., Khan O.A., DeVries G.H. Antibodies to the axolemma-enriched fraction in the cerebrospinal fluid and serum of patients with multiple sclerosis and other neurological diseases. Mult. Scler. 1997, 3:363-369.
39. Lily O., Palace J., Vincent A. Serum autoantibodies to cell surface determinants in multiple sclerosis: a flow cytometric study. Brain 2004, 127:269-279.
40. Mathey E.K., Derfuss T., Storch M.K., Williams K.R., Hales K., Woolley D.R., Al-Hayani A., Davies S.N., Rasband M.N., Olsson T., Moldenhauer A., Velhin S., Hohlfeld R., Meinl E., Linington C. Neurofascin as a novel target for autoantibody-mediated axonal injury. J. Exp. Med. 2007, 204:2363-2372.
41. Derfuss T., Parikh K., Velhin S., Braun M., Mathey E., Krumbholz M., Kümpfel T., Moldenhauer A., Rader C., Sonderegger P., Pöllmann W., Tiefenthaller C., Bauer J., Lassmann H., Wekerle H., Karagogeos D., Hohlfeld R., Linington C., Meinl E. Contactin-2/TAG-1-directed autoimmunity is identified in multiple sclerosis patients and mediates gray matter pathology in animals. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:8302-8307.
42. Höftberger R., Aboul-Enein F., Brueck W., Lucchinetti C., Rodriguez M., Schmidbauer M., Jellinger K., Lassmann H. Expression of major histocompatibility complex class I molecules on the different cell types in multiple sclerosis lesions. Brain Pathol. 2004, 14:43-50.
43. Huizinga R., Heijmans N., Schubert P., Gschmeissner S., 't Hart B.A., Herrmann H., Amor S. Immunization with neurofilament light protein induces spastic paresis and axonal degeneration in Biozzi ABH mice. J. Neuropathol. Exp. Neurol. 2007, 66:295-304.
44. Huizinga R., Hintzen R.Q., Assink K., van Meurs M., Amor S. T-cell responses to neurofilament light protein are part of the normal immune repertoire. Int. Immunol. 2009, 21:433-441.
45. Huizinga R., Gerritsen W., Heijmans N., Amor S. Axonal loss and gray matter pathology as a direct result of autoimmunity to neurofilaments. Neurobiol. Dis. 2008, 32:461-470.
46. Antony J.M., van Marle G., Opii W., Butterfield D.A., Mallet F., Yong V.W., Wallace J.L., Deacon R.M., Warren K., Power C. Human endogenous retrovirus glycoprotein-mediated induction of redox reactants causes oligodendrocyte death and demyelination. Nat. Neurosci. 2004, 7:1088-1095.
47. Kennedy P.G.E. Neurological aspects of lentiviral infections in animals, Baillieres. Clin. Neurol. 1992, 1:41-59.
48. Kennedy P.G.E., Steiner I. On the possible viral aetiology of multiple sclerosis. Qjm 1994, 87:523-528.
49. Opsahl M.L., Kennedy P.G.E. Early and late HHV-6 gene transcripts in multiple sclerosis lesions and normal appearing white matter. Brain 2005, 128:516-527.
50. Cermelli C., Jacobson S. Viruses and multiple sclerosis. Viral Immunol. 2000, 13:255-267.
51. Stüve O., Racke M., Hemmer B. Viral pathogens in multiple sclerosis: an intriguing (hi)story. Arch. Neurol. 2004, 61:1500-1502.
52. Christensen T. The role of EBV in MS pathogenesis. Int. MS. J. 2006, 13:52-57.
53. Berger J.R., Tornatore C., Major E.O., Bruce J., Shapshak P., Yoshioka M., Houff S., Sheremata W., Horton G.F., Landy H. Relapsing and remitting human immunodeficiency virus-associated leukoencephalomyelopathy. Ann. Neurol. 1992, 31:34-38.
54. Saresella M., Rolland A., Marventano I., Cavarretta R., Caputo D., Marche P., Perron H., Clerici M. Multiple sclerosis-associated retroviral agent (MSRV)-stimulated cytokine production in patients with relapsing-remitting multiple sclerosis. Mult. Scler. 2009, 15:443-447.
55. I. Tsunoda, R.S. Fujinami, Neuropathogenesis of Theiler's murine encephalomyelitis virus infection, a viral model for multiple sclerosis, J. Neuroimmune Pharmacol., in press.
56. Tsunoda I., Fujinami R.S. Theiler's murine encephalomyelitis virus. Persistent Viral Infections 1999, 517-536. John Wiley & Sons Ltd., Chichester, West Sussex, (Chapter 25). R. Ahmed, I.S.Y. Chen (Eds.).
57. Tsunoda I., Iwasaki Y., Terunuma H., Sako K., Ohara Y. A comparative study of acute and chronic diseases induced by two subgroups of Theiler's murine encephalomyelitis virus. Acta Neuropathol. 1996, 91:595-602.
58. Melvold R.W., Jokinen D.M., Knobler R.L., Lipton H.L. Variations in genetic control of susceptibility to Theiler's murine encephalomyelitis virus (TMEV)-induced demyelinating disease. I. Differences between susceptible SJL/J and resistant BALB/c strains map near the T cell beta-chain constant gene on chromosome 6. J. Immunol. 1987, 138:1429-1433.
59. Rodriguez M., Leibowitz J., David C.S. Susceptibility to Theiler's virus-induced demyelination. Mapping of the gene within the H-2D region. J. Exp. Med. 1986, 163:620-631.
60. Roussarie J.-P., Ruffié C., Brahic M. The role of myelin in Theiler's virus persistence in the central nervous system. PLoS Pathog. 2007, 3:e23.
61. Borrow P., Welsh C.J., Nash A.A. Study of the mechanisms by which CD4+ T cells contribute to protection in Theiler's murine encephalomyelitis. Immunology 1993, 80:502-506.
62. Tsunoda I., Fujinami R.S. TMEV and neuroantigens: myelin genes and proteins, molecular mimicry, epitope spreading, and autoantibody-mediated remyelination. Experimental Model of Multiple Sclerosis 2005, 593-616. Springer, New York, NY, (Chapter B2). E. Lavi, C.S. Constantinescu (Eds.).
63. Olson J.K., Miller S.D. The role of T cells and the innate immune system in the pathogenesis of Theiler's virus demyelinating disease. Experimental Model of Multiple Sclerosis 2005, 645-657. Springer, New York, NY, (Chapter B5). E. Lavi, C.S. Constantinescu (Eds.).
64. Miller S.D., Vanderlugt C.L., Begolka W.S., Pao W., Yauch R.L., Neville K.L., Katz-Levy Y., Carrizosa A., Kim B.S. Persistent infection with Theiler's virus leads to CNS autoimmunity via epitope spreading. Nat. Med. 1997, 3:1133-1136.
65. Rodriguez M., Sriram S. Successful therapy of Theiler's virus-induced demyelination (DA strain) with monoclonal anti-Lyt-2 antibody. J. Immunol. 1988, 140:2950-2955.
66. + T cell clones and hybridomas following virus infection. Encyclopedia of Neuroscience 2009, 619-625. Springer-Verlag, GmbH Berlin Heidelberg. M.D. Binder, N. Hirokawa, U. Windhorst (Eds.).
67. + cytotoxic T cells during Theiler's murine encephalomyelitis virus infection: implications for autoimmunity. J. Virol. 2002, 76:12834-12844.
68. + T-cell clones following virus infection. J. Virol. 2005, 79:14640-14646.
69. Fujinami R.S., Rosenthal A., Lampert P.W., Zurbriggen A., Yamada M. Survival of athymic (nu/nu) mice after Theiler's murine encephalomyelitis virus infection by passive administration of neutralizing monoclonal antibody. J. Virol. 1989, 63:2081-2087.
70. Yamada M., Zurbriggen A., Fujinami R.S. Monoclonal antibody to Theiler's murine encephalomyelitis virus defines a determinant on myelin and oligodendrocytes, and augments demyelination in experimental allergic encephalomyelitis. J. Exp. Med. 1990, 171:1893-1907.
71. Lipton H.L., Twaddle G., Jelachich M.L. The predominant virus antigen burden is present in macrophages in Theiler's murine encephalomyelitis virus-induced demyelinating disease. J. Virol. 1995, 69:2525-2533.
72. Rossi C.P., Delcroix M., Huitinga I., McAllister A., van Rooijen N., Claassen E., Brahic M. Role of macrophages during Theiler's virus infection. J. Virol. 1997, 71:3336-3340.
73. Rodriguez M., Quddus J. Effect of cyclosporin A, silica quartz dust, and protease inhibitors on virus-induced demyelination. J. Neuroimmunol. 1986, 13:159-174.
74. Roos R.P., Wollmann R. DA strain of Theiler's murine encephalomyelitis virus induces demyelination in nude mice. Ann. Neurol. 1984, 15:494-499.
75. Fan J., Son K.-N., Arslan S.Y., Liang Z., Lipton H.L. Theiler's murine encephalomyelitis virus leader protein is the only nonstructural protein tested that induces apoptosis when transfected into mammalian cells. J. Virol. 2009, 83:6546-6553.
76. Lucchinetti C.F., Brück W., Rodriguez M., Lassmann H. Distinct patterns of multiple sclerosis pathology indicates heterogeneity on pathogenesis. Brain Pathol. 1996, 6:259-274.
77. Ozawa K., Suchanek G., Breitschopf H., Brück W., Budka H., Jellinger K., Lassmann H. Patterns of oligodendroglia pathology in multiple sclerosis. Brain 1994, 117:1311-1322.
78. Vartanian T., Li Y., Zhao M., Stefansson K. Interferon-gamma-induced oligodendrocyte cell death: implications for the pathogenesis of multiple sclerosis. Mol. Med. 1995, 1:732-743.
79. Pender M.P., Nguyen K.B., McCombe P.A., Kerr J.F.R. Apoptosis in the nervous system in experimental allergic encephalomyelitis. J. Neurol. Sci. 1991, 104:81-87.
80. Tsunoda I., Kurtz C.I.B., Fujinami R.S. Apoptosis in acute and chronic central nervous system disease induced by Theiler's murine encephalomyelitis virus. Virology 1997, 228:388-393.
81. Rose J.W., Hill K.E., Wada Y., Kurtz C.I.B., Tsunoda I., Fujinami R.S., Cross A.H. Nitric oxide synthase inhibitor, aminoguanidine, reduces inflammation and demyelination produced by Theiler's virus infection. J. Neuroimmunol. 1998, 81:82-89.
82. Tsunoda I., Kuang L.-Q., Libbey J.E., Fujinami R.S. Axonal injury heralds virus-induced demyelination. Am. J. Pathol. 2003, 162:1259-1269.
83. Dal Canto M.C., Lipton H.L. Primary demyelination in Theiler's virus infection. An ultrastructural study. Lab. Invest. 1975, 33:626-637.
84. McGavern D.B., Murray P.D., Rivera-Quiñones C., Schmelzer J.D., Low P.A., Rodriguez M. Axonal loss results in spinal cord atrophy, electrophysiological abnormalities and neurological deficits following demyelination in a chronic inflammatory model of multiple sclerosis. Brain 2000, 123:519-531.
85. McGavern D.B., Murray P.D., Rodriguez M. Quantitation of spinal cord demyelination, remyelination, atrophy, and axonal loss in a model of progressive neurologic injury. J. Neurosci. Res. 1999, 58:492-504.
86. Sathornsumetee S., McGavern D.B., Ure D.R., Rodriguez M. Quantitative ultrastructural analysis of a single spinal cord demyelinated lesion predicts total lesion load, axonal loss, and neurological dysfunction in a murine model of multiple sclerosis. Am. J. Pathol. 2000, 157:1365-1376.
87. Tsunoda I. Axonal degeneration as a self-destructive defense mechanism against neurotropic virus infection. Future Virol. 2008, 3:579-593.
88. Deb C., LaFrance-Corey R.G., Zoecklein L., Papke L., Rodriguez M., Howe C.L. Demyelinated axons and motor function are protected by genetic deletion of perforin in a mouse model of multiple sclerosis. J. Neuropathol. Exp. Neurol. 2009, 68:1037-1048.
89. Das Sarma J., Kenyon L.C., Hingley S.T., Shindler K.S. Mechanisms of primary axonal damage in a viral model of multiple sclerosis. J. Neurosci. 2009, 29:10272-10280.
90. Tsunoda I., Tanaka T., Saijoh Y., Fujinami R.S. Targeting inflammatory demyelinating lesions to sites of Wallerian degeneration. Am. J. Pathol. 2007, 171:1563-1575.
91. Zipp F., Aktas O. The brain as a target of inflammation: common pathways link inflammatory and neurodegenerative diseases. Trends Neurosci. 2006, 29:518-527.
92. Konno H., Yamamoto T., Iwasaki Y., Suzuki H., Saito T., Terunuma H. Wallerian degeneration induces Ia-antigen expression in the rat brain. J. Neuroimmunol. 1989, 25:151-159.
93. Konno H., Yamamoto T., Suzuki H., Yamamoto H., Iwasaki Y., Ohara Y., Terunuma H., Harata N. Targeting of adoptively transferred experimental allergic encephalitis lesion at the sites of wallerian degeneration. Acta Neuropathol. 1990, 80:521-526.
94. Bodini B., Khaleeli Z., Cercignani M., Miller D.H., Thompson A.J., Ciccarelli O. Exploring the relationship between white matter and gray matter damage in early primary progressive multiple sclerosis: an in vivo study with TBSS and VBM. Hum. Brain Mapp. 2009, 30:2852-2861.
95. Abe Y., Yamamoto T., Sugiyama Y., Watanabe T., Saito N., Kayama H., Kumagai T. Apoptotic cells associated with Wallerian degeneration after experimental spinal cord injury: a possible mechanism of oligodendroglial death. J. Neurotrauma 1999, 16:945-952.
96. Crowe M.J., Bresnahan J.C., Shuman S.L., Masters J.N., Beattie M.S. Apoptosis and delayed degeneration after spinal cord injury in rats and monkeys. Nat. Med. 1997, 3:73-76.
97. Saito N., Yamamoto T., Watanabe T., Abe Y., Kumagai T. Implications of p53 protein expression in experimental spinal cord injury. J. Neurotrauma 2000, 17:173-182.
98. Matute C., Alberdi E., Domercq M., Pérez-Cerdá F., Pérez-Samartín A., Sánchez-Gómez M.V. The link between excitotoxic oligodendroglial death and demyelinating diseases. Trends Neurosci. 2001, 24:224-230.
99. Carlson N.G., Hill K.E., Tsunoda I., Fujinami R.S., Rose J.W. The pathologic role for COX-2 in apoptotic oligodendrocytes in virus induced demyelinating disease: implications for multiple sclerosis. J. Neuroimmunol. 2006, 174:21-31.
100. Li S., Mealing G.A.R., Morley P., Stys P.K. Novel injury mechanism in anoxia and trauma of spinal cord white matter: glutamate release via reverse Na+-dependent glutamate transport. J. Neurosci. 1999, 19:RC16.
101. Allt G., Ghabriel M.N. Demyelination: a failure of cell communication?. J. Neurol. Sci. 1982, 57:287-290.
102. Barres B.A., Raff M.C. Axonal control of oligodendrocyte development. J. Cell Biol. 1999, 147:1123-1128.
103. Raff M.C., Barres B.A., Burne J.F., Coles H.S., Ishizaki Y., Jacobson M.D. Programmed cell death and the control of cell survival: lessons from the nervous system. Science 1993, 262:695-700.
104. Roussarie J.-P., Ruffié C., Edgar J.M., Griffiths I., Brahic M. Axon myelin transfer of a non-enveloped virus. PLoS One 2007, 2:e1331.
105. Gebauer F., Hentze M.W. Molecular mechanisms of translational control. Nat. Rev. Mol. Cell. Biol. 2004, 5:827-835.
106. Holcik M., Sonenberg N. Translational control in stress and apoptosis. Nat. Rev. Mol. Cell. Biol. 2005, 6:318-327.
107. Agol V.I. Picornavirus genome: an overview. Molecular Biology of Picornaviruses 2002, 127-148. AMS Press, Washington, D.C. B.L. Semler, E. Wimmer (Eds.).
108. I.R.E.S. Database, Inserm, The French Institute of Health and Medical Research. http://www.rangueil.inserm.fr/IRESdatabase/.
109. Holcik M., Lefebvre C., Yeh C., Chow T., Korneluk R.G. A new internal-ribosome-entry-site motif potentiates XIAP-mediated cytoprotection. Nat. Cell. Biol. 1999, 1:190-192.
110. Coldwell M.J., Mitchell S.A., Stoneley M., MacFarlane M., Willis A.E. Initiation of Apaf-1 translation by internal ribosome entry. Oncogene 2000, 19:899-905.
111. Sherrill K.W., Byrd M.P., Van Eden M.E., Lloyd R.E. BCL-2 translation is mediated via internal ribosome entry during cell stress. J. Biol. Chem. 2004, 279:29066-29074.
112. Tsunoda I., McCright I.J., Kuang L.-Q., Zurbriggen A., Fujinami R.S. Hydrocephalus in mice infected with a Theiler's murine encephalomyelitis virus variant. J. Neuropathol. Exp. Neurol. 1997, 56:1302-1313.
113. Coleman M.P., Perry V.H. Axon pathology in neurological disease: a neglected therapeutic target. Trends Neurosci. 2002, 25:532-537.
114. Gillingwater T.H., Ribchester R.R. Compartmental neurodegeneration and synaptic plasticity in the Wld(s) mutant mouse. J. Physiol. 2001, 534:627-639.
115. Perry V.H., Lunn E.R., Brown M.C., Cahusac S., Gordon S. Evidence that the rate of Wallerian degeneration is controlled by a single autosomal dominant gene. Eur. J. Neurosci. 1990, 2:408-413.
116. Glass J.D., Griffin J.W. Neurofilament redistribution in transected nerves: evidence for bidirectional transport of neurofilaments. J. Neurosci. 1991, 11:3146-3154.
117. Glass J.D., Griffin J.W. Retrograde transport of radiolabeled cytoskeletal proteins in transected nerves. J. Neurosci. 1994, 14:3915-3921.
118. Watson D.F., Glass J.D., Griffin J.W. Redistribution of cytoskeletal proteins in mammalian axons disconnected from their cell bodies. J. Neurosci. 1993, 13:4354-4360.
119. Tsunoda I., Tanaka T., Terry E.J., Fujinami R.S. Contrasting roles for axonal degeneration in an autoimmune versus viral model of multiple sclerosis: when can axonal injury be beneficial?. Am. J. Pathol. 2007, 170:214-226.